Temozolomide

CAS No. 85622-93-1

Temozolomide( NSC-362856 | CCRG-81045 | TZM )

Catalog No. M16206 CAS No. 85622-93-1

An alkylating agent used as a treatment of some brain cancers, astrocytoma and glioblastoma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 38 In Stock
25MG 61 In Stock
50MG 74 In Stock
100MG 87 In Stock
200MG 116 In Stock
500MG 152 In Stock
1G 224 In Stock

Biological Information

  • Product Name
    Temozolomide
  • Note
    Research use only, not for human use.
  • Brief Description
    An alkylating agent used as a treatment of some brain cancers, astrocytoma and glioblastoma.
  • Description
    An alkylating agent used as a treatment of some brain cancers, astrocytoma and glioblastoma; a prodrug and an imidazotetrazine derivative of the alkylating agent dacarbazine.Chemotherapeutic Agents Approved(In Vitro):Temozolomide (TZM) is a methylating agent that crosses the blood-brain barrier and is indicated for malignant gliomas and metastatic melanomas. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system (MR). Determination of the IC50 for Temozolomide (TZM) in different cell lines gave values ranging from 14.1 to 234.6 μM that fell into two clearly differentiated groups: cell lines with low IC50 values (<50 μM), which include A172 (14.1±1.1 μM) and LN229 cells (14.5±1.1 μM), and those with high IC50 values (>100 μM), which include SF268 (147.2±2.1 μM) and SK-N-SH cells (234.6±2.3 μM). (In Vivo):Temozolomide (TZM), as a single agent, does not significantly increase mdian survival time (MST) with respect to control. Noteworthy, intracranial injection of NU1025, immediately before the administration of 100 or 200 mg/kg Temozolomide, significantly increases lifespans with respect to controls or to groups treated with Temozolomide only. When Temozolomide is fractionated, the increase in lifespan (ILS) obtained with this schedule is higher than that observed when NU1025 is combined with a single injection of Temozolomide (statistical comparison of survival curves: NU1025 intracranially+Temozolomide 100 mg/kg×2 vs NU1025+Temozolomide 200 mg/kg; P=0.023).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    NSC-362856 | CCRG-81045 | TZM
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DNA Alkylator
  • Recptor
    DNAreplication
  • Research Area
    Cancer
  • Indication
    Chemotherapeutic

Chemical Information

  • CAS Number
    85622-93-1
  • Formula Weight
    194.1508
  • Molecular Formula
    C6H6N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 33.33 mg/mL
  • SMILES
    O=C(C1=C(N2C=N1)N=NN(C)C2=O)N
  • Chemical Name
    Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Rao JU, et al. Sci Rep. 2017 Aug 11;7(1):7865. 2. Tateishi K, et al. Cancer Res. 2017 Aug 1;77(15):4102-4115. 3. Beier D, et al. Cancer Res. 2008 Jul 15;68(14):5706-15.
molnova catalog
related products
  • Trabectedin

    Trabectedin (Ecteinascidin-743, ET-743, Ecteinascidin)?is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata that shows remarkably anticancer activity in a variety of in vitro and in vivo systems.

  • Glufosfamide

    A conjugate of glucose and active alkylating moiety of ifosfamide with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters.

  • Melflufen

    Melflufen ?is a novel dipeptide and alkylating prodrug of melphalan, inhibits angiogenesis in vitro and in vivo; shows cytotoxic activity against lymphoma cell lines with IC50 of 0.011-0.92 uM, also shows significantly lower IC50 than melphalan in multiple myeloma cells.